Precision BioSciences, Inc.

NASDAQ:DTIL

Biotechnology

Healthcare
$7.10 +1.69%

+$0.11 today

Market cap
$198.34M
Beta
1.28
P/E (TTM)
-1.9
EPS (TTM)
-$3.47
52W Low $3.53High $8.82

Volume 0.37M

Average 0.31M

DTIL Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Precision BioSciences, Inc.NASDAQ: DTIL

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to -170.2%

Net margin was -170.2% in Q1 FY2026, up 70743.6 pp from a year earlier. On a trailing-twelve-month basis it was -98.7%, down 55.7 pp year over year. Over 3 fiscal years it widened by 308.8 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.

What to watch

Whether net margin reaches the consensus estimate from 4 analysts of -319.4% for the fiscal year ending Dec 2026, down from -136.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-170.2%-226.4 pp QoQ
Last fiscal yearDec 2025
-136.0%-146.5 pp YoY
LTMMar 2026
-98.7%-55.7 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+70743.6 pp+127686.1 pp+56942.4 pp
1 year-146.5 pp-183.4 pp-36.9 pp
3 years+308.8 pp+10.2 pp-298.5 pp
5 years+133.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-136.0%
Year-over-year change
-146.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How DTIL compares with its peers on the latest reported figures

  • DTIL's LTM Mar 2026 net margin of -98.7% is the 3rd highest of the 6 companies compared; the peer median is -324.8%.
  • Its year-over-year change of -55.7 pp is the 2nd highest of 4, against a peer median of -283.7 pp.
  • Over three fiscal years its change of +308.8 pp compares with a peer median of +156.0 pp.
DTIL Competitors Peer median
Net Margin for DTIL and competitors
Company Period LTM level YoY 3-year change
QTTBQ32 Bio Inc.LTM Mar 202661.9% —+699.1 pp
HRTXHeron Therapeutics, Inc.LTM Mar 2026-20.5% -15.3 pp+156.0 pp
DTILPrecision BioSciences, Inc.LTM Mar 2026-98.7% -55.7 pp+308.8 pp
GOSSGossamer Bio, Inc.LTM Mar 2026-324.8% -283.7 pp—
RNAAtrium Therapeutics, Inc.FY2025-411.9% ——
ALECAlector, Inc.LTM Mar 2026-680.8% -541.1 pp-579.4 pp
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding DTIL) -324.8%-283.7 pp+156.0 pp

Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue115.53M25.1M48.73M68.7M34.26M
Cost of Revenue00002.75M
Gross Profit115.53M25.1M48.73M68.7M31.51M
Gross Margin100.0%100.0%100.0%100.0%92.0%
Research & Development115.24M46.12M53.38M59.56M54.17M
Selling, General & Admin39.67M41.28M39.09M35.3M32.24M
Operating Expenses154.91M87.41M92.46M94.86M83.66M
Depreciation & Amortization10.2M9M8.26M4.58M2.75M
EBITDA(20.27M)(62.79M)(32.04M)13.53M(42.43M)
EBITDA Margin-17.5%-250.2%-65.8%19.7%-123.8%
Operating Income(39.38M)(62.31M)(43.74M)(26.16M)(52.15M)
Operating Margin-34.1%-248.3%-89.8%-38.1%-152.2%
Interest Income208K3.47M7.69M6.76M4.24M
Interest Expense132K1.11M2.23M1.78M1.42M
Other Income / Expenses8.77M(10.6M)1.21M33.33M5.54M
Income Before Tax(30.6M)(72.91M)(42.53M)7.17M(46.61M)
Pre-Tax Margin-26.5%-290.5%-87.3%10.4%-136.0%
Income Tax Expense00000
Net Income(30.6M)(111.64M)(61.32M)7.17M(46.61M)
Net Margin-26.5%-444.8%-125.8%10.4%-136.0%
EPS (Basic)(15.60)(38.10)(15.96)1.05(3.63)
EPS (Diluted)(15.60)(38.10)(15.96)1.04(3.63)
Weighted Avg Shares1.96M2.93M3.84M6.83M12.83M
Weighted Avg Shares (Diluted)1.96M2.93M3.84M6.88M12.83M

Precision BioSciences, Inc.

NASDAQ:DTIL

Intrinsic Alpha fair value

Locked

Current Price

$7.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.